SUZHOU, China, June 2, 2025 /PRNewswire/ -- XellSmart Biomedical Co., Ltd. (Suzhou/Shanghai, China) is a leading biotechnology company dedicated to the development of innovative iPSC-derived cell therapies. To date, the company has received seven Investigational New Drug (IND) approvals...
Hence then, the article about xellsmart secures fda clearance for three phase i inds of allogeneic ipsc derived cell therapies targeting major cns diseases parkinson s diseases spinal cord injury and als was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( XellSmart Secures FDA Clearance for Three Phase I INDs of Allogeneic iPSC-Derived Cell Therapies Targeting Major CNS Diseases: Parkinson's Diseases, Spinal Cord Injury and ALS )
Also on site :
- Bisignano says Social Security Administration’s phone helpline wait times have reached a record low
- US undermining World Cup with entry bans – Indian coach
- Savannah Chrisley Makes Huge Announcement About New Career Venture That Promises To Spill a Lot of Tea